SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Oncology Pharmacy Practice
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Ferguson, L. R.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Ferguson, L. R.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Occupational health and staff monitoring: A genetic toxicologist's viewpoint

Lynnette R. Ferguson, MSc, DPhil (Oxon)

Cancer Research Laboratory, Private Bag 92019, Auckland, New Zealand

This is a summary of some of the points raised in a round table discussion on occupational health and in two workshops on staff monitoring, held as part of ISOPP IV. It is not intended as a comprehensive review on these issues. It is, however, intended to focus discussion on some of the controversial areas from the perspective of a genetic toxicologist. Pharmacists who have points to add or disagree with, or who wish to discuss or debate these issues further might address such comments as "Letters to the editor" in this journal.

Key Words: Environmental monitoring; biomonitoring • epidemiology • anticancer drugs • mutagenicity • carcinogenicity • birth defects.

Journal of Oncology Pharmacy Practice, Vol. 1, No. 3, 49-54 (1995)
DOI: 10.1177/107815529500100310


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement